Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects concerns about the company's future revenue, influenced by ...

signs that the stock is at least attempting to trace out a bottoming pattern. Mark looks for these bottom formations in certain trading patterns. Here's a list of Argus Research BUY-rated stocks ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders purchased 32,455 put options on the company. This represents an increase of ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

This conservative guidance, coupled with a projected mid-single-digit percentage decline in sales, led to a 4.3% drop in Biogen's stock price following the announcement. For the current fiscal ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

The stock's fall snapped a seven-day winning streak.